Leukemias characterized by mutations in EZH2, DNMT3A, or ASXL1 or SET-NUP214 or RUNX1-EVI1 fusions also show overexpression of HOXA and MEIS1 [59,60,61,62], and it might hypothetically be reasonable to expect a response to MI; future clinical studies will provide more confirmation about these novel targets. This evidence concerns the gene MEIS1 and leukemia.